Genfleet Receives IND Approval for KRAS G12C Inhibitor

“As a frequently altered proto-oncogene, RAS mutation is widespread among patients of non-small cell lung cancer, pancreatic cancer, colorectal cancer, etc. Around 80% of KRAS mutation subtypes occur in codon 12; in addition, G12C mutations amount to 1/3 of all KRAS G12C mutations with poor prognosis. Our development scheme will be built upon the trial data and the resistance mechanism research of other KRAS inhibitors, while referring to the epidemiological data in China. Based on biomarkers obtained in the trial, we will also optimize our precision treatment plans and pave the way for the potential of combination therapies.”

“RAS used to be an undruggable target and the basic research of RAS protein has spanned decades. There was no KRAS G12C inhibitor moving into clinical trials when we started our program, which is consistent with GenFleet’s mission of developing cutting-edge products with novel mechanisms. Preclinical data sufficiently differentiated GFH925 from other KRAS G12C inhibiting products, and our strategy highly conforms to the latest industrial initiative of providing better options for patients as the ultimate goal of drug discovery and development. We look forward to continuous progress of our pipeline and better healthcare solution for patients worldwide.”